Editas Other Liab vs Cash Analysis
EDIT Stock | USD 6.00 0.32 5.63% |
Editas Medicine financial indicator trend analysis is much more than just examining Editas Medicine latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Editas Medicine is a good investment. Please check the relationship between Editas Medicine Other Liab and its Cash accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.
Other Liab vs Cash
Other Liab vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Editas Medicine Other Liab account and Cash. At this time, the significance of the direction appears to have strong relationship.
The correlation between Editas Medicine's Other Liab and Cash is 0.78. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Cash in the same time period over historical financial statements of Editas Medicine, assuming nothing else is changed. The correlation between historical values of Editas Medicine's Other Liab and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Editas Medicine are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Other Liab i.e., Editas Medicine's Other Liab and Cash go up and down completely randomly.
Correlation Coefficient | 0.78 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Other Liab
Cash
Cash refers to the most liquid asset of Editas Medicine, which is listed under current asset account on Editas Medicine balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Editas Medicine customers. The amounts must be unrestricted with restricted cash listed in a different Editas Medicine account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from Editas Medicine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.Enterprise Value is likely to gain to about 921.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 218.7M | 245.7M | 241.2M | 167.7M | Cost Of Revenue | 5.1M | 6.3M | 6.1M | 5.8M |
Editas Medicine fundamental ratios Correlations
Click cells to compare fundamentals
Editas Medicine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Editas Medicine fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 508.9M | 572.6M | 677.5M | 514.3M | 499.2M | 395.9M | |
Short Long Term Debt Total | 29.1M | 26.1M | 26.4M | 43.9M | 36.5M | 33.9M | |
Other Current Liab | 24.8M | 24.0M | 20.2M | 31.3M | 34.6M | 36.3M | |
Total Current Liabilities | 60.0M | 58.2M | 46.9M | 60.1M | 63.2M | 40.9M | |
Total Stockholder Equity | 262.4M | 393.6M | 553.6M | 360.7M | 349.1M | 239.8M | |
Other Liab | 163.2M | 101.5M | 60.9M | 60.7M | 69.8M | 71.4M | |
Property Plant And Equipment Net | 39.6M | 39.1M | 43.3M | 59.2M | 45.7M | 35.0M | |
Net Debt | (209.1M) | (113.5M) | (177.1M) | (97.6M) | (87.1M) | (91.5M) | |
Retained Earnings | (549.2M) | (665.2M) | (857.7M) | (1.1B) | (1.2B) | (1.2B) | |
Accounts Payable | 5.8M | 6.4M | 5.1M | 9.5M | 8.3M | 5.3M | |
Cash | 238.2M | 139.7M | 203.5M | 141.5M | 123.7M | 146.9M | |
Non Current Assets Total | 45.0M | 153.5M | 170.2M | 157.6M | 158.3M | 82.0M | |
Non Currrent Assets Other | 107K | 4.7M | 6.8M | 5.3M | 4.7M | 3.3M | |
Other Assets | 1.7M | 4.7M | 6.8M | 5.3M | 6.0M | 6.3M | |
Cash And Short Term Investments | 457.1M | 511.8M | 619.9M | 437.4M | 323.1M | 338.9M | |
Common Stock Shares Outstanding | 50.0M | 58.6M | 67.6M | 68.7M | 76.0M | 49.3M | |
Liabilities And Stockholders Equity | 508.9M | 572.6M | 677.5M | 514.3M | 499.2M | 395.9M | |
Non Current Liabilities Total | 186.5M | 120.8M | 77.0M | 93.5M | 86.8M | 115.2M | |
Other Current Assets | 6.3M | 10.9M | 7.2M | 7.3M | 7.5M | 4.3M | |
Other Stockholder Equity | 811.5M | 1.1B | 1.4B | 1.4B | 1.6B | 1.7B | |
Total Liab | 246.4M | 179.0M | 123.8M | 153.6M | 150.1M | 156.1M | |
Property Plant And Equipment Gross | 39.6M | 39.1M | 58.8M | 80.7M | 72.0M | 41.4M | |
Total Current Assets | 463.8M | 419.1M | 507.3M | 356.8M | 340.8M | 314.0M | |
Accumulated Other Comprehensive Income | 107K | (46K) | (493K) | (3.6M) | 198K | 207.9K | |
Property Plant Equipment | 39.6M | 14.0M | 17.1M | 15.6M | 17.9M | 23.1M | |
Net Tangible Assets | 262.4M | 393.6M | 553.6M | 360.7M | 414.8M | 250.7M | |
Current Deferred Revenue | 23.5M | 20.9M | 11.3M | 8.2M | 9.5M | 14.2M | |
Net Receivables | 418K | 6.0M | 267K | 5.1M | 10.2M | 10.7M | |
Short Term Debt | 5.8M | 6.8M | 10.3M | 11.1M | 12.2M | 9.5M | |
Short Term Investments | 219.0M | 262.4M | 296.3M | 202.8M | 199.5M | 195.2M | |
Capital Surpluse | 811.5M | 1.1B | 1.4B | 1.4B | 1.7B | 854.8M | |
Retained Earnings Total Equity | (549.2M) | (665.2M) | (857.7M) | (1.1B) | (970.3M) | (921.8M) | |
Capital Lease Obligations | 29.1M | 26.1M | 26.4M | 43.9M | 36.5M | 36.2M |
Pair Trading with Editas Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Editas Stock
0.76 | EQ | Equillium Earnings Call This Week | PairCorr |
Moving against Editas Stock
0.66 | ELYM | Eliem Therapeutics | PairCorr |
0.58 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
0.45 | VALN | Valneva SE ADR | PairCorr |
0.41 | XFOR | X4 Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Revenue Per Share 0.876 | Quarterly Revenue Growth (0.89) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.